US FDA orders new GLP-1 warning labels over potential blindness risk
Published · Updated
What happened
The US Food and Drug Administration ordered new warning labels for GLP-1 drugs including Ozempic, Wegovy and Mounjaro on November 10, citing a potential blindness risk.
Why it matters
A label change by the US FDA can alter prescribing guidance, informed-consent language, insurer policies and post-market safety monitoring in other jurisdictions. Because GLP-1 medicines are used at scale for diabetes and weight management, even a precautionary warning can change clinician behavior and patient demand within days.
On November 10, the US Food and Drug Administration ordered updated prescribing information for GLP-1 medicines including Ozempic, Wegovy and Mounjaro to add a warning about a potential risk of vision loss or blindness. The action is a discrete regulatory change by a major reference-market authority and is relevant to health systems where these medicines are widely prescribed. For the UAE, the near-term issue is whether local regulators and providers mirror the warning, adjust patient advice, or increase adverse-event reporting.
Watch for
UAE Ministry of Health and Prevention circular on GLP-1 prescribing or patient counseling issued by 2026-11-14 Dubai Health Authority safety notice or formulary guidance referencing GLP-1 vision-risk labeling by 2026-11-14 Abu Dhabi Public Health Centre or Department of Health reporting instruction to providers on ophthalmic adverse events linked to GLP-1 use by 2026-11-14 US FDA publication of updated label language in drug safety databases for semaglutide and tirzepatide products by 2026-11-13
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made